Company news
GeoVax Labs, Inc. news in 2020
GeoVax Labs, Inc.'s news releases, calls and decks from 2020, newest first.
GeoVax Announces License Agreement With NIH to Support Continued Advancements in Vaccine Development
November 29, 2020
GeoVax Reports 2020 Third Quarter Financial Results and Provides Corporate Update
November 4, 2020
GeoVax Announces License Agreement with NIH to Support COVID-19 Vaccine Development
October 25, 2020
GeoVax Announces Closing of $12.8 Million Public Offering and Uplisting to Nasdaq
September 28, 2020
GeoVax Announces Pricing of $12.8 Million Public Offering; Uplisting to Nasdaq and Reverse Stock Split
September 23, 2020
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Marburg Virus Showing 100% Protection
September 2, 2020
GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer
August 25, 2020
GeoVax Announces Clinical Trial Initiation of Novel Combination Therapy Utilizing MVA62B to Induce Remission in HIV-Positive Patients
August 23, 2020
GeoVax Announces Collaboration for Development of Sudan Ebolavirus and Marburg Virus Vaccines
August 12, 2020
GeoVax Reports 2020 Second Quarter Financial Results and Provides Corporate Update
August 9, 2020
GeoVax Announces Closing of $1 Million Private Placement
June 28, 2020
GeoVax Labs, Inc. Announces Approval for Trading on OTCQB Venture Market
June 3, 2020
GeoVax Reports 2020 First Quarter Financial Results and Provides Corporate Update
May 5, 2020
GeoVax and Sino Biological Establish Exclusive Supply Agreement for Research Grade Bioreagents Related to SARS-Cov-2 (COVID-19) Vaccine Development
April 29, 2020
GeoVax Reports 2019 Year-End Financial Results And Provides Corporate Update
March 24, 2020
GeoVax Progresses in Coronavirus (COVID-19) Vaccine Development Program
March 17, 2020
GeoVax Provides Update on Coronavirus (COVID-19) Vaccine Development Program
March 3, 2020
GeoVax Announces Reverse Stock Split
January 22, 2020